Literature DB >> 9823428

In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents.

D R Budman1, A Calabro, W Kreis.   

Abstract

New cytotoxics with significant activity both in preclinical and clinical situations continued to be applied in the clinic by empiric means. The use of defined cell lines allows unanticipated antagonism between agents to be identified and to suggest synergistic combinations which need to be tested. By means of a semi-automated MTT assay and median effect analysis, we have identified antagonism in two couplets being evaluated in the clinic: etoposide with paclitaxel and vinorelbine with gemcitabine. Optimal use of these agents in man may require spacing these agents in time to prevent an adverse drug interaction between the agents which may diminish the potential response rate.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9823428     DOI: 10.1097/00001813-199809000-00005

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  6 in total

1.  The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines.

Authors:  Daniel R Budman; Julia Tai; Anthony Calabro; Veena John
Journal:  Invest New Drugs       Date:  2010-06-09       Impact factor: 3.850

Review 2.  Modelling and simulation in the development and use of anti-cancer agents: an underused tool?

Authors:  Ferdinand Rombout; Leon Aarons; Mats Karlsson; Anthony Man; France Mentré; Peter Nygren; Amy Racine; Hans Schaefer; Jean-Louis Steimer; Iñaki Troconiz; Achiel van Peer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-12       Impact factor: 2.745

3.  Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid.

Authors:  Kathryn M Camacho; Sunny Kumar; Stefano Menegatti; Douglas R Vogus; Aaron C Anselmo; Samir Mitragotri
Journal:  J Control Release       Date:  2015-04-25       Impact factor: 9.776

4.  Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system.

Authors:  Daniel R Budman; Anthony Calabro; Lisa Rosen; Martin Lesser
Journal:  Anticancer Drugs       Date:  2012-03       Impact factor: 2.248

5.  DAFODIL: A novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapy.

Authors:  Kathryn M Camacho; Stefano Menegatti; Douglas R Vogus; Anusha Pusuluri; Zoë Fuchs; Maria Jarvis; Michael Zakrewsky; Michael A Evans; Renwei Chen; Samir Mitragotri
Journal:  J Control Release       Date:  2016-03-24       Impact factor: 9.776

6.  Clinical trials and progress with paclitaxel in ovarian cancer.

Authors:  Sanjeev Kumar; Haider Mahdi; Christopher Bryant; Jay P Shah; Gunjal Garg; Adnan Munkarah
Journal:  Int J Womens Health       Date:  2010-11-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.